In May of 2008 this health writer published an almost unbelievable report of four published studies of 4-7 year remissions from colon and breast cancer facilitated by weekly injection of an abundant sugar-like protein in human blood serum called Gc macrophage activating factor (Gc-MAF). A year later I wrote a follow-up report showing lack of interest by the cancer care community in this remarkable development.
Cancer cells secrete an enzyme called nagalase that completely blocks the conversion of Gc-protein to Gc-MAF which is needed to kill cancer cells via activation of white-blood cells known as macrophages. Macrophages track down and engulf cancer cells.
The startling aspect of these published reports is that the cancer community is ignoring them when there are simply no published studies showing long-term cures for any adult cancers. For example, typical survival for lung and colon cancer is 2 years or less.
I was originally alerted to these reports by a researcher in Ohio, Tim Hubbell. Otherwise they may have remained in obscurity.
GcMAF treatment for cancer was first described in 1993. Two decades have past and this therapy has been agonizingly slow to reach the cancer clinic.
Now doctors at the Saisei Mirai Clinic in Kobe, Japan report they have successfully treated 345 patient from April of 2011 to March 2013 and they present three cases that responded to treatment in their most recent report published in Anticancer Research.
- Patient #1: a 71-year-old male with diagnosed cancer of his thymus gland that had spread to his lungs received 24 weeks of therapy. No progression of the cancer was found 12 months following completion of treatment.
- Patient #2: a 74-year-old male diagnosed with prostate cancer that had spread to multiple bone sites underwent 12 weeks of treatment. Bone scans were normal 9 months after initiation of therapy and the tumors had disappeared.
- Patient #3: a 72-year-old woman with spreading liver cancer underwent 24 weeks of therapy plus radiation. There was no evidence of recurrence or metastatic (spreading) disease on PET or CT scans 12 months after treatment.
The treatment team at the Saisei Mirai Clinic uses a combination of therapies that include (a) weekly Gc-MAF injections; (b) high-dose intravenous vitamin C therapy twice a week; (c) oral alpha lipoic antioxidant supplementation 600 mg/day; (d) oral vitamin D3, 5000-10,000 IU/day.
“All of these therapies aim to strengthen and activate the immune system and take a holistic approach to fighting cancer rather than a localized approach that is common with conventional therapies such as radiation and surgery,” their report says.
They indicate, when tumors are large, they may need to resort to surgery or radiation to de-bulk a tumor.
These investigators in Japan say: “We have used this multi-modality integrative immunotherapy-based approach in nearly 400 patients with cancer. The results of this integrative immunotherapy look hopeful.”
The world is watching. Conventional cancer treatment is so ineffective, and so arduous, and so anxiety ridden and so very expensive. Is cancer being cured before our eyes? Would oncologists give up their fat incomes billing for infusions of $25,000 anti-cancer drugs in their offices for this far-less expensive therapy now being used at a single center in Japan?
There should be worldwide acclaim over this promising development. News agencies should be flocking to Kobe, Japan for interviews with these researchers. Again, like before, all these developments are being ignored by the cancer care industry and the news media. This reporter has to break the news on the internet.
Three of the four regimens that comprise this combination therapy are generally available in the US and other developed nations. Dr. Andrew Saul has written how to obtain a prescription for intravenous vitamin C for hospitalized patients. Information onhow doctors should administer intravenous vitamin C therapy is available online.
This author has described a dietary supplement regimen where IP6 rice bran extract (2000-12,000 mg) can be used to activate white blood cells (neutrophils) to literally blow up tumor cells. IP6 has been demonstrated to “prime” white blood cells so they will track down bacteria or tumor cells in the blood circulation.
